Abstract 576P
Background
As third-generation EGFR tyrosine kinase inhibitors (TKIs) have become the frontline treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC), heterogenous responses are commonly observed. This study aimed to investigate the influence of clonal architecture involving EGFR and co-occurring genetic mutations on the response to EGFR-TKIs.
Methods
We gathered a large, homogenous cohort of treatment-naive patients with advanced EGFR-mutant NSCLC who underwent tissue next-generation sequencing (NGS) and received first-line treatment with third-generation EGFR-TKI. Variant allele frequency (VAF) from NGS was normalized based on copy numbers of genes. The VAF of each mutation relative to the maximum VAF in each sample was computed to determine clonality.
Results
A total of 160 eligible patients were enrolled at SYSUCC from January 2019 to January 2023. The aberrant TP53 gene was the most frequent co-alteration, accounting for 68.1% of total cases. EGFR (51.9%) was the most common gene occupying the maximum VAF, followed by TP53 (28.8%), RBM10 (4.4%), RB1 (1.9%), and PIK3CA (1.3%). Both EGFR and TP53 mutations exhibited potential as dominant or subordinate clones in advanced NSCLC. Notably, EGFR-mutant patients receiving first-line third-generation EGFR-TKIs demonstrated significantly prolonged progress-free survival (PFS) when EGFR dominance clone prevailed over EGFR sub-clonal status (median PFS: 22.0m VS. 15.0m, P=0.008). Conversely, TP53 dominance clone correlated with diminished treatment outcomes compared to TP53 sub-clonal cases (median PFS: 15.1m VS. 17.7m, P=0.05). Multivariate analysis confirmed EGFR clonality and TP53 clonality as independent predictors of EGFR-TKI response. Moreover, the clinical impact of EGFR and TP53 clonality was validated in an independent cohort.
Conclusions
Our proof-of-concept study illuminates the clinical significance of both EGFR and TP53 clonality in EGFR-mutant patients with advanced NSCLC who received first-line third-generation EGFR-TKIs. EGFR or TP53 mutations exhibit potential as dominant or subordinate clones, intricately linked to the efficacy of third-generation EGFR-TKIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
382P - Oral health disparities in privileged and underprivileged tribes of south India: A study of the prevalence of precancerous oral lesions
Presenter: Shanavas Palliyal
Session: Poster Display
Resources:
Abstract
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract